IM Cannabis (IMCC) & Its Competitors Head to Head Analysis

IM Cannabis (NASDAQ: IMCC) is one of 43 public companies in the “Medicinals & botanicals” industry, but how does it weigh in compared to its peers? We will compare IM Cannabis to related businesses based on the strength of its dividends, profitability, risk, earnings, institutional ownership, valuation and analyst recommendations.

Earnings & Valuation

This table compares IM Cannabis and its peers top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
IM Cannabis $11.86 million -$21.42 million -5.98
IM Cannabis Competitors $220.78 million -$89.53 million -16.22

IM Cannabis’ peers have higher revenue, but lower earnings than IM Cannabis. IM Cannabis is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Institutional and Insider Ownership

13.7% of IM Cannabis shares are held by institutional investors. Comparatively, 17.9% of shares of all “Medicinals & botanicals” companies are held by institutional investors. 30.9% of shares of all “Medicinals & botanicals” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares IM Cannabis and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
IM Cannabis -62.31% -20.56% -13.99%
IM Cannabis Competitors -196.99% -84.80% -18.10%

Analyst Ratings

This is a breakdown of recent ratings and target prices for IM Cannabis and its peers, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
IM Cannabis 0 0 3 0 3.00
IM Cannabis Competitors 221 604 580 12 2.27

IM Cannabis currently has a consensus price target of $8.75, suggesting a potential upside of 165.96%. As a group, “Medicinals & botanicals” companies have a potential upside of 43.87%. Given IM Cannabis’ stronger consensus rating and higher possible upside, equities analysts clearly believe IM Cannabis is more favorable than its peers.

Summary

IM Cannabis beats its peers on 8 of the 12 factors compared.

IM Cannabis Company Profile

IM Cannabis Corp. engages in breeding, growing, and supply of medical cannabis products in Israel, Germany, and Canada. It offers strains under the Roma, Dairy Queen, London, Tel Aviv, Paris, and Pandora Box brands; and CBD oil products under the IMC brand. The company also offers its intellectual property related services to the medical cannabis industry. IM Cannabis Corp. is headquartered in Tel Aviv-Yafo, Israel.

Receive News & Ratings for IM Cannabis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IM Cannabis and related companies with MarketBeat.com's FREE daily email newsletter.